Bartosz Korczowski1, Tinatin Antadze, Manana Giorgobiani, Martin E Stryjewski, Alena Jandourek, Alexander Smith, Tanya O'Neal, John S Bradley. 1. From the *Pediatric Department, Medical College, University of Rzeszów, Rzeszów, Poland; †Department of Abdominal and Traumatology-Orthopedic Surgery, JSC M. Iashvili Children's Central Hospital, Tbilisi, Georgia; ‡Department of Pediatric Surgery, LTD, Children's New Clinic, Tbilisi, Georgia; §Division of Infectious Diseases, Department of Medicine, Centro de Educación Médica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina; ¶Department of Clinical Development, Cerexa, Inc., Oakland, CA; and ‖Division of Infectious Diseases, Department of Pediatrics, University of California at San Diego, Rady Children's Hospital, San Diego, CA.
Abstract
BACKGROUND:Ceftaroline has in vitro activity against bacterial isolates, including methicillin-resistant Staphylococcus aureus. This is the first study to investigate ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections (ABSSSIs). METHODS: A multicenter, observer-blinded study (NCT01400867) in pediatric patients (2 months-17 years of age) with ABSSSIs. Patients were randomized 2:1 to receive intravenous (IV) ceftaroline fosamil or IV comparator (vancomycin or cefazolin, plus optional aztreonam) with optional switch to oral antibacterials from Day 4. Safety and clinical outcomes were assessed. RESULTS: Of 163 enrolled patients, 159 received treatment. Treatment groups were comparable for baseline characteristics. Rates of study drug-related treatment-emergent adverse events were similar for ceftaroline fosamil [22% (23/106)] and comparator [23% (12/53)]. One serious adverse event, considered to be related to IV study drug, occurred in the ceftaroline fosamil group (hypersensitivity). In both the treatment groups, 85% (ceftaroline fosamil, 91/107 and comparator, 44/52) of the modified intent-to-treat population achieved early clinical response (≥20% reduction in infection area from baseline). Clinical cure rates at test-of-cure were high [ceftaroline fosamil, 94% (101/107) and comparator, 87% (45/52)]. For patients evaluated 8 to 15 days after the last dose of any antibiotic (IV or oral), from whom methicillin-resistant Staphylococcus aureus was initially isolated, a favorable microbiologic response (reflecting the efficacy of oral/IV therapy and capturing a relapse or reinfection) was achieved with ceftaroline fosamil [89% (16/18)] and comparator [57% (4/7)]. CONCLUSIONS:Ceftaroline fosamil, with optional oral switch, was as well-tolerated and effective in pediatric patients with ABSSSIs as comparator therapy.
RCT Entities:
BACKGROUND:Ceftaroline has in vitro activity against bacterial isolates, including methicillin-resistant Staphylococcus aureus. This is the first study to investigate ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections (ABSSSIs). METHODS: A multicenter, observer-blinded study (NCT01400867) in pediatric patients (2 months-17 years of age) with ABSSSIs. Patients were randomized 2:1 to receive intravenous (IV) ceftaroline fosamil or IV comparator (vancomycin or cefazolin, plus optional aztreonam) with optional switch to oral antibacterials from Day 4. Safety and clinical outcomes were assessed. RESULTS: Of 163 enrolled patients, 159 received treatment. Treatment groups were comparable for baseline characteristics. Rates of study drug-related treatment-emergent adverse events were similar for ceftaroline fosamil [22% (23/106)] and comparator [23% (12/53)]. One serious adverse event, considered to be related to IV study drug, occurred in the ceftaroline fosamil group (hypersensitivity). In both the treatment groups, 85% (ceftaroline fosamil, 91/107 and comparator, 44/52) of the modified intent-to-treat population achieved early clinical response (≥20% reduction in infection area from baseline). Clinical cure rates at test-of-cure were high [ceftaroline fosamil, 94% (101/107) and comparator, 87% (45/52)]. For patients evaluated 8 to 15 days after the last dose of any antibiotic (IV or oral), from whom methicillin-resistant Staphylococcus aureus was initially isolated, a favorable microbiologic response (reflecting the efficacy of oral/IV therapy and capturing a relapse or reinfection) was achieved with ceftaroline fosamil [89% (16/18)] and comparator [57% (4/7)]. CONCLUSIONS:Ceftaroline fosamil, with optional oral switch, was as well-tolerated and effective in pediatric patients with ABSSSIs as comparator therapy.
Authors: Rebecca G Same; Alice J Hsu; Sara E Cosgrove; Eili Y Klein; Joe Amoah; Adam L Hersh; Matthew P Kronman; Pranita D Tamma Journal: J Pediatric Infect Dis Soc Date: 2021-05-28 Impact factor: 3.164
Authors: Phylinda L S Chan; Lynn McFadyen; Andrea Quaye; Heidi Leister-Tebbe; Victoria M Hendrick; Jennifer Hammond; Susan Raber Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-05-01